Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Improving neoadjuvant and perioperative therapy in non-small-cell lung cancer.

Nature reviews. Clinical oncology·2026

Same author

plasmaCHORD: A Machine Learning Approach to Distinguish Clonal Hematopoiesis-Derived Variants in Liquid Biopsies from Patients with Solid Tumors.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Same author

Serial Plasma Comprehensive Genomic Profiling Captures Therapy Resistance and Guides Management of Non-Small Cell Lung Cancer.

Cancer research communications·2026

Same author

How Much Is Enough? Ultra-Low Doses of Immunotherapy to Improve Access and Affordability.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Same author

Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer. Reply.

The New England journal of medicine·2025

Same author

Real-world outcomes of neoadjuvant chemoimmunotherapy in patients with nonsmall cell lung cancer: Predictors of surgery, pathologic complete response, and event-free survival.

Cancer·2025

Search research articles

Related Experiment Video

Updated: May 12, 2025

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Immunotherapy for resectable lung cancer.

Colum Dennehy¹, Michael R Conroy¹, Patrick M Forde¹

¹Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

|May 7, 2025

Summary

This summary is machine-generated.

Neoadjuvant and perioperative immunotherapy shows promise for early-stage lung cancer, improving survival and reducing recurrence. Challenges in patient selection and managing side effects remain key areas for research.

Keywords:

adjuvant immune checkpoint immunotherapy localized lung cancer neoadjuvant non–small cell lung cancer (NSCLC)perioperative resectable surgery

More Related Videos

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Published on: January 19, 2019

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

Related Experiment Videos

Last Updated: May 12, 2025

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Published on: January 19, 2019

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

Area of Science:

Oncology
Immunology

Background:

Lung cancer is a leading global health concern.
Immune checkpoint blockade is a standard therapy for advanced and early-stage resectable lung cancer.

Purpose of the Study:

To review the current status and future directions of neoadjuvant and perioperative immunotherapy in lung cancer.
To analyze clinical trial findings, safety profiles, and impacts on recurrence and survival.

Main Methods:

Review of clinical trials and existing literature on neoadjuvant and perioperative immunotherapy for resectable lung cancer.
Analysis of efficacy, safety, patient selection, treatment schedules, and surgical impact.

Main Results:

Neoadjuvant and perioperative immunotherapy demonstrates early efficacy and impacts disease recurrence and survival in resectable lung cancer.
Key challenges include optimizing patient selection, treatment timing, managing immune-related adverse events, and surgical considerations.

Conclusions:

Immunotherapy offers a promising therapeutic strategy for surgically resectable lung cancer.
Further research is needed to overcome challenges and establish optimal protocols for neoadjuvant and perioperative immunotherapy.